Barclays PLC Has $754,000 Position in Bausch Health Companies Inc. (NYSE:BHC)

Barclays PLC lessened its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 42.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 93,523 shares of the company’s stock after selling 69,249 shares during the period. Barclays PLC’s holdings in Bausch Health Companies were worth $754,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Bausch Health Companies during the fourth quarter worth $56,000. Bank of Nova Scotia acquired a new stake in shares of Bausch Health Companies in the 4th quarter valued at approximately $83,000. Tobam boosted its stake in Bausch Health Companies by 10.4% during the 4th quarter. Tobam now owns 15,034 shares of the company’s stock worth $121,000 after acquiring an additional 1,422 shares during the last quarter. Norges Bank bought a new stake in Bausch Health Companies in the fourth quarter valued at approximately $141,000. Finally, DGS Capital Management LLC acquired a new stake in Bausch Health Companies in the fourth quarter worth $143,000. Institutional investors own 78.65% of the company’s stock.

Analysts Set New Price Targets

BHC has been the topic of several recent analyst reports. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Thursday, May 1st. Jefferies Financial Group reaffirmed a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Finally, Royal Bank of Canada lifted their target price on Bausch Health Companies from $8.50 to $10.00 and gave the company a “sector perform” rating in a research report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Bausch Health Companies presently has an average rating of “Hold” and an average target price of $7.42.

Bausch Health Companies Stock Down 3.4 %

BHC opened at $4.76 on Wednesday. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $9.85. The business has a 50 day moving average of $5.94 and a 200-day moving average of $7.17. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -39.66, a PEG ratio of 0.37 and a beta of 0.34.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The business had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. As a group, analysts expect that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.